Preclinical Cancer Landscape discusses the issues in preclinical-to-clinical translatability of molecularly targeted cancer therapies and the need to better align tumour biology in patients With a strong focus on the status, challenges, prospects and the need of robustness of preclinical cancer research, the book acknowledges that the bar for reproducibility in performing and presenting preclinical studies must be raised to facilitate a transparent discovery process that frequently and consistently leads to significant patient benefit. In 22 chapters this book describes the current status of preclinical research in multiple cancers. This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field. " Preclinical landscape in cancer research " is written by experts in the field and informed with facts directly from manufacturers. Pharmaceutical scientists, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.
Les mer
1. Liver cancer: current status of preclinical research 2. Pancreatic cancer: current status of preclinical research 3. Heart cancer: current status of preclinical research 4. Bone cancer: current status of preclinical research 5. Spleen cancer: current status of preclinical research 6. ENT cancer: current status of preclinical research 7. Brain/CSN cancer: current status of preclinical research 8. Skin cancer: current status of preclinical research 9. Lung cancer: current status of preclinical research 10. Thorax cancer: current status of preclinical research 11. Thyroid cancer: current status of preclinical research 12. Kidney-adrenal cancer: current status of preclinical research 13. Urinary tracker cancer: current status of preclinical research 14. Breast cancer: current status of preclinical research 15. Blood cancer: current status of preclinical research 16. Prostate cancer: current status of preclinical research 17. Gynecologic cancer: current status of preclinical research 18. Stomach and intestinal cancer: current status of preclinical research 19. Plura and peritoneum cancer: current status of preclinical research 20. Ocular cancer: current status of preclinical research 21. Oral cancer: current status of preclinical research 22. Growth Inhibitory Effects of Unsaturated Linoleinic Acid with Conjugated Double Bonds for Colon Cancer Prevention
Les mer
Provides an exclusive updated overview of scientific knowledge, achievements, and findings in the field of the preclinical landscape in cancer
Contains current studies of the preclinical research of 25 different cancer types Provides essential information on the most recent developments in preclinical cancer research Explains current technology and its applications of preclinical cancer research Holds contributions from oncologists, biomedical engineers, pharmaceutical scientists and manufacturers
Les mer

Produktdetaljer

ISBN
9780443316562
Publisert
2025-06-09
Utgiver
Elsevier Science Publishing Co Inc
Vekt
870 gr
Høyde
235 mm
Bredde
191 mm
Aldersnivå
P, 06
Språk
Product language
Engelsk
Format
Product format
Heftet
Antall sider
416

Biografisk notat

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com) Yashwant Pathak is a Professor and Associate Dean for faculty affairs at the Taneja College of Pharmacy at the University of South Florida, Tampa, USA. Prof. Pathak is also an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. His area of research is in health care education, nanotechnology, drug delivery systems, and nutraceuticals.